Clinical Trials

Accrual Status
Limit to SWOG Trials

1045 Results

View
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Status Notes
Active as of 4/22/2026.
Research Committee(s)
Genitourinary Cancer
Activated
04-22-2026
ClinicalTrials.gov Registry Number
NCT07383441
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
SN2426

A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Sarcoma
Activated
01-28-2026
ClinicalTrials.gov Registry Number
07042295
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2433

Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
12-26-2025
ClinicalTrials.gov Registry Number
NCT06998940
Open
Phase
Accrual
6%
SWOG Clinical Trial Number
21CTP.HN01

Phase II Study of Amivantamab carboPlatin and pacliTaxel in recurrent metastatic Head and Neck cancer (CAPT-HN) Study Synopsis
Status Notes
Activation - Effective 09/15/2025

SWOG Clinical Trials Partinerships
https://www.swogctp.org/trials/21ctphn01/
Research Committee(s)
SWOG CTP
Head and Neck Cancer
Activated
09-15-2025
ClinicalTrials.gov Registry Number
07062354
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Status Notes
This study is open to accrual, effective 9/8/2025 at 12:00 p.m. PT.
Research Committee(s)
Lung Cancer
Activated
09-08-2025
Open
Phase
Accrual
10%
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Status Notes
Active as of 9/4/2025.
Research Committee(s)
Genitourinary Cancer
Activated
09-04-2025
ClinicalTrials.gov Registry Number
07061964